OncologyTube Professional - Patients Click Here
213,778 video views
Loading........
Description: Benjamin Philip Levy, MD, talks about the data from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st line non-small cell lung cancer (NSCLC)
01:05
Benjamin Philip Levy, MD, talks about the data from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st line non-small cell lung cancer (NSCLC)
by:obr | 23 views
02:45
Primo N. Lara, Jr., MD, explains whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which TKIs seem to be the most successful in 1st line renal cell carcinoma (RCC)
by:obr | 16 views
01:13
Howard A. "Skip" Burris III, MD, FACP, FASCO, explains some of the new and exciting concepts in clinical trial design
by:obr | 7 views
00:44
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
by:obr | 7 views
01:29
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting
by:obr | 12 views
01:39
Julie Gralow, MD, talks about how to differentiate CDK4/6 inhibitors and whether they can be used interchangeably.
by:obr | 12 views
01:37
Primo N. Lara, Jr., MD, explains the convenience factor of oral TKIs influences decisions related to advanced renal cell carcinoma (RCC) treatment
by:obr | 10 views
02:10
Eunice Wang, MD, talks about The most exciting data coming out of the 2018 Annual Meeting
by:obr | 14 views
00:40
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how Watson is helping to identify and match cancer patients to clinical trials at the point of care
by:obr | 13 views
01:40
Benjamin Philip Levy, MD, explains whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and what levels of PD-L1 expression are actionable
by:obr | 16 views

About obr
Description: OBR is the most comprehensive digital platform for oncology focused news and information: We aggregate, customize and prioritize daily oncology news and publications (OBR Daily for industry and providers, RSS newsfeeds) We research, develop and publish original content (OBR green) We create and produce customized training programs for pharmaceutical professionals (Oncology Business Dynamics) We conduct, interpret, analyze and produce original research (On-Telligence) We publish informational resources and editorial perspective to our websites (OBR Radar, Pipeline Online, Blog, Twitter, OBR Finance, News Pulse, KOL Commentary, and others)

Links
Channel Url:

Website:


Social Links: